Treatment of Locally Advanced Breast Cancer With Letrozole in Postmenopausal Women
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 112
- Registration Number
- NCT00237133
- Locations
- 🇧🇷
Novartis Investigative Site, Vitoria/ES, Brazil
Study of Safety and Efficacy of Letrozole Monotherapy as Second-line Endocrine Therapy in Postmenopausal Patients With Advanced Breast Cancer Who Received Previous Anti-estrogen Treatment
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 47
- Registration Number
- NCT00237198
- Locations
- 🇯🇵
Novartis Investigative Site, Shizuoka, Japan
Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study)
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2012-05-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 72
- Registration Number
- NCT00237172
Effect of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastasis
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2011-03-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 284
- Registration Number
- NCT00237159
Study of High-dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 31
- Registration Number
- NCT00237211
- Locations
- 🇯🇵
Novartis Investigative Site, Saitama, Japan
A Study of the Efficacy and Safety of Imatinib Mesylate in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing C-kit Gene
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2014-08-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 148
- Registration Number
- NCT00237185
- Locations
- 🇺🇸
Dana Farber Cancer Institute Dept of Sarcoma Oncology, Boston, Massachusetts, United States
🇺🇸Oregon Health Sciences University Dept. of Oregon Health Sci., Portland, Oregon, United States
🇫🇮Novartis Investigative Site, Helsinki, Finland
Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 38
- Registration Number
- NCT00237146
- Locations
- 🇻🇪
Novartis Investigative Site, Caracas, Venezuela
Open Label Study of Postmenopausal Women With ER and /or PgR Positive Breast Cancer Treated With Letrozole
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2009-11-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT00237224
- Locations
- 🇲🇽
Novartis Investigative Site, Guadalajara, Zacatecas, México DF, Mexico
Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-10-10
- Last Posted Date
- 2011-06-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1683
- Registration Number
- NCT00235391
- Locations
- 🇮🇹
Azienda Ospedali Vittorio Emanuele, Ferrarotto e San Bambino, Catania, Italy
🇮🇹PresidioOspedaliero S. Luigi Curro, Catania, Italy
🇺🇸PCTI, Columbus, Ohio, United States
Efficacy, Safety and Tolerability of Co-artemether in Non-immune Travelers
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-10-05
- Last Posted Date
- 2012-04-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT00233337
© Copyright 2024. All Rights Reserved by MedPath